Sigilon Therapeutics, Inc.

NasdaqGS:SGTX Stock Report

Market Cap: US$56.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Sigilon Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Rogerio Coelho

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage29.7%
CEO tenure5.6yrs
CEO ownershipn/a
Management average tenure2.3yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet

Apr 17
Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet

Sigilon Therapeutics GAAP EPS of -$0.44, revenue of $2.88M

Aug 04

Sigilon Therapeutics names Philip Ashton-Rickardt as chief scientific officer

Jun 14

What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?

Mar 04
What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?

Sigilon Therapeutics' MPS-1 gene therapy an Orphan Drug in U.S.

Dec 17

CEO Compensation Analysis

How has Rogerio Coelho's remuneration changed compared to Sigilon Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$30m

Mar 31 2023n/an/a

-US$37m

Dec 31 2022US$2mUS$601k

-US$44m

Sep 30 2022n/an/a

-US$55m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$72m

Dec 31 2021US$6mUS$578k

-US$77m

Sep 30 2021n/an/a

-US$75m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$61m

Dec 31 2020US$810kUS$528k

-US$55m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$51m

Mar 31 2020n/an/a

-US$47m

Dec 31 2019US$723kUS$508k

-US$44m

Compensation vs Market: Rogerio's total compensation ($USD2.02M) is above average for companies of similar size in the US market ($USD754.53K).

Compensation vs Earnings: Rogerio's compensation has been consistent with company performance over the past year.

CEO

Rogerio Coelho (59 yo)

5.6yrs

Tenure

US$2,024,671

Compensation

Dr. Rogerio Vivaldi Coelho, M.D., M.B.A., is Independent Director of Crinetics Pharmaceuticals, Inc. from January 03, 2022. He was Chief Global Therapeutic Operations Officer and Executive Vice President o...

Leadership Team

NamePositionTenureCompensationOwnership
Rogerio Coelho
President5.6yrsUS$2.02mno data
Philip Ashton-Rickardt
Chief Scientific Officer2.2yrsUS$902.19k0%
$ 0
Robert Langer
Co-Founder & Member of Scientific Advisory Boardno dataUS$101.90kno data
Daniel Anderson
Co-Founder & Member of Scientific Advisory Boardno dataUS$46.92kno data
Omid Veiseh
Co-Founderno datano datano data
José Oberholzer
Co-Founderno datano datano data
Arturo Vegas
Co-Founderno datano datano data
Josias Fantato Pontes
CFO, Principal Accounting Officer & Treasurer1.5yrsno data0%
$ 0
Bernd Kullmann
Senior VP and Head of Operations & Project Managementless than a yearno datano data
Matthew Kowalsky
Chief of Staff3.6yrsno data0%
$ 0
Robert Windsor
VP & Head of Investor Relations2.3yrsno datano data
Olivia Kelly
Senior VP & Head of Diabetes Research5.6yrsno datano data

2.3yrs

Average Tenure

57.5yo

Average Age

Experienced Management: SGTX's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rogerio Coelho
President5.6yrsUS$2.02mno data
Robert Langer
Co-Founder & Member of Scientific Advisory Boardno dataUS$101.90kno data
Daniel Anderson
Co-Founder & Member of Scientific Advisory Boardno dataUS$46.92kno data
Michael Rosenblatt
Member of Scientific Advisory Board3.6yrsno datano data
Ulrik Nielsen
Member of Scientific Advisory Board3.6yrsno datano data
Stephen Newman Oesterle
Independent Director7.6yrsUS$51.24k0%
$ 0
Robert R. Ruffolo
Independent Director7.6yrsUS$44.74k0%
$ 0
Douglas Cole
Independent Chairman of The Board8.6yrsUS$87.74k0%
$ 0
John Cox
Independent Director4.3yrsUS$44.74k0%
$ 0
Constance Cepko
Member of Scientific Advisory Board5.8yrsno datano data
Eric Shaff
Independent Director5.8yrsUS$54.74k0%
$ 0
Kavita Patel
Independent Director3.2yrsUS$45.80k0%
$ 0

5.7yrs

Average Tenure

60yo

Average Age

Experienced Board: SGTX's board of directors are considered experienced (5.7 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.